Paratek Pharmaceuticals (PRTK) Scheduled to Post Quarterly Earnings on Tuesday

Share on StockTwits

Paratek Pharmaceuticals (NASDAQ:PRTK) is set to announce its earnings results after the market closes on Tuesday, August 6th. Analysts expect the company to announce earnings of ($1.16) per share for the quarter.

Paratek Pharmaceuticals (NASDAQ:PRTK) last posted its quarterly earnings data on Wednesday, May 8th. The specialty pharmaceutical company reported ($1.10) EPS for the quarter, topping analysts’ consensus estimates of ($1.19) by $0.09. The business had revenue of $1.60 million for the quarter, compared to analyst estimates of $0.89 million. Paratek Pharmaceuticals had a negative return on equity of 232.61% and a negative net margin of 642.70%. On average, analysts expect Paratek Pharmaceuticals to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Paratek Pharmaceuticals stock opened at $3.00 on Monday. The company has a quick ratio of 13.95, a current ratio of 14.06 and a debt-to-equity ratio of 14.48. The business has a 50-day simple moving average of $3.61. The company has a market capitalization of $99.84 million, a price-to-earnings ratio of -0.84 and a beta of 1.81. Paratek Pharmaceuticals has a 52 week low of $2.87 and a 52 week high of $12.30.

PRTK has been the topic of several research reports. Zacks Investment Research lowered Paratek Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, July 26th. HC Wainwright restated a “buy” rating on shares of Paratek Pharmaceuticals in a research note on Wednesday, June 26th. ValuEngine upgraded Paratek Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday. LADENBURG THALM/SH SH restated a “buy” rating on shares of Paratek Pharmaceuticals in a research note on Thursday, May 9th. Finally, Wedbush restated an “outperform” rating and set a $12.00 price target (down from $17.00) on shares of Paratek Pharmaceuticals in a research note on Thursday, May 9th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $19.33.

Paratek Pharmaceuticals Company Profile

Paratek Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon biology and tetracycline chemistry in the United States. Its lead product candidates include omadacycline, an intravenous and oral antibiotic for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound designed for use in the treatment of acne and rosacea.

Recommended Story: Is the QQQ ETF safe?

Earnings History for Paratek Pharmaceuticals (NASDAQ:PRTK)

Receive News & Ratings for Paratek Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Morningstar, Inc.  Chairman Sells $1,280,264.30 in Stock
Morningstar, Inc. Chairman Sells $1,280,264.30 in Stock
Scotts Miracle-Gro Co  COO Sells $1,262,849.48 in Stock
Scotts Miracle-Gro Co COO Sells $1,262,849.48 in Stock
Insider Selling: The Carlyle Group LP  COO Sells $1,259,903.30 in Stock
Insider Selling: The Carlyle Group LP COO Sells $1,259,903.30 in Stock
Sensata Technologies Holding PLC  EVP Sells $1,248,731.59 in Stock
Sensata Technologies Holding PLC EVP Sells $1,248,731.59 in Stock
Insider Selling: HMS Holdings Corp  SVP Sells $1,227,787.50 in Stock
Insider Selling: HMS Holdings Corp SVP Sells $1,227,787.50 in Stock
SunPower Co.  CEO Sells $1,211,400.00 in Stock
SunPower Co. CEO Sells $1,211,400.00 in Stock


© 2006-2019 Ticker Report